Literature DB >> 17520717

Magnetic resonance imaging to assess acute changes in atrial and ventricular parameters after transcatheter closure of atrial septal defects.

Christof Burgstahler1, Jochen Wöhrle, Matthias Kochs, Thorsten Nusser, Christine Löffler, Markus Kunze, Martin Höher, Meinrad P Gawaz, Vinzenz Hombach, Nico Merkle.   

Abstract

PURPOSE: To evaluate acute changes in atrial and ventricular parameters by the use of cardiac magnetic resonance imaging (MRI) in patients with percutaneous transcatheter atrial septal defects (ASD) closure.
MATERIALS AND METHODS: The study included 14 patients (six males and eight females, 45 +/- 18 years) with congenital ASD. Cardiac MRI (1.5T Philips Intera CV) was performed before and within 24 hours after transcatheter ASD closure. Right atrial (RA) and left atrial (LA) dimensions, as well as right (RV) and left (LV) ventricular end-diastolic (ED) volumes were determined. Atrial size was assessed by planimetry of the maximum RA and LA areas in a standard four-chamber view, and ventricular volumes were calculated according to a modified Simpson's rule in short-axis views.
RESULTS: The mean RA decreased significantly from 27.6 +/- 6.4 cm(2) before closure to 24.4 +/- 5.6 cm(2) after the procedure (P = 0.0018), whereas the LA area did not change (24.1 +/- 4.7 cm(2) vs. 23.8 +/- 5.2 cm(2), P = 0.76). The RV volumes, volume index, and ejection fraction (EF) decreased significantly from 229 +/- 64 mL to 181 +/- 43 mL (P < 0.001, average reduction = 19% +/- 15%), from 126.0 +/- 37.2 mL/m(2) to 96.6 +/- 28.6 mL/m(2) (P < 0.0001) and from 64 +/- 5% to 58% +/- 7% (P = 0.01), respectively. The LV volumes and volume index remained unchanged (114 +/- 25 mL vs. 118 +/- 22 mL, P = 0.18, 63.5 +/- 13.5 mL/m(2) vs. 63.0 +/- 17.4 mL/m(2), P = 0.83). Left-right shunting decreased from 40% +/- 15% to 9% +/- 15% (P < 0.001).
CONCLUSION: Cardiac MRI can reveal detailed information on acute changes in shunt fraction and ventricular dimensions after ASD closure. ASD closure by percutaneous transcatheter device implantation results within 24 hours in a significant reduction of shunt fraction, RA and RV sizes, and RV function, whereas LA and LV dimensions remain unchanged. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2007        PMID: 17520717     DOI: 10.1002/jmri.20911

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  5 in total

1.  Impact of transcatheter closure of atrial septal defects on cardiac function.

Authors:  Hideki Tashiro; Kenji Suda; Yoshifumi Tananari; Shinichi Itou
Journal:  J Med Ultrason (2001)       Date:  2012-03-09       Impact factor: 1.314

2.  Influence of percutaneous atrial septal defect closure on inter- and intra-ventricular mechanical dyssynchrony in adults: evaluation of strain pattern.

Authors:  Qi-Zhe Cai; Yu Liang; Zhen-Hui Zhu; Xiu-Zhang Lu
Journal:  Int J Cardiovasc Imaging       Date:  2014-02-07       Impact factor: 2.357

3.  Right Ventricular Pump Efficiency in Secundum-Type Atrial Septal Defect.

Authors:  Wei-Tsung Lai; Ho-Ping Yu; Chang-Chyi Lin; Wei-Hsian Yin; Tsung-Yu Ko; Juey-Jen Hwang; Lung-Chun Lin; Kuan-Chih Huang
Journal:  Acta Cardiol Sin       Date:  2022-01       Impact factor: 2.672

4.  Cardiac MRI findings to differentiate athlete's heart from hypertrophic (HCM), arrhythmogenic right ventricular (ARVC) and dilated (DCM) cardiomyopathy.

Authors:  J Kübler; C Burgstahler; J M Brendel; S Gassenmaier; F Hagen; K Klingel; S-C Olthof; K Blume; B Wolfarth; K A L Mueller; S Greulich; P Krumm
Journal:  Int J Cardiovasc Imaging       Date:  2021-05-21       Impact factor: 2.357

5.  Percutaneous closure of atrial septal defects leads to normalisation of atrial and ventricular volumes.

Authors:  Karen S L Teo; Benjamin K Dundon; Payman Molaee; Kerry F Williams; Angelo Carbone; Michael A Brown; Matthew I Worthley; Patrick J Disney; Prashanthan Sanders; Stephen G Worthley
Journal:  J Cardiovasc Magn Reson       Date:  2008-12-01       Impact factor: 5.364

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.